Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
Synta Drug for Metastatic Melanoma Not Dead Yet (?)
November 3, 2009
Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com
Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated...
Delcath Phase III trial for metastatic melanoma completes enrollment
November 3, 2009
Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com
The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submis...
Particle Beam Technology - Costly and a limited utility
October 26, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly...
Particle Beam Radiation Therapy (PBRT) life saving technology but who will pay?
October 22, 2009
Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov
PBRT is an exciting technology that has emerged as a life saver for children and many adults with head/neck , eye and other difficult to treat cancers. Proton Centers require massive investments from $100-250 million. Payor groups from Medicare to commercial plans are faced with whether to pay forthis...
Plexxikon Drug for Melanoma Continues to Show Great Promise
October 14, 2009
Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com
The new drug PLX-4032, being developed by Plexxikon and Roche, continues to show impressive short term results in melanoma patients with specific BRAF mutations, with a reported 70% tumor response rate.
Triple negative Breast Cancer Strategies
October 14, 2009
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...
Expanding Treatment Options for Prostate Cancer
October 11, 2009
Medicare to cover controversial prostate treatment | www.philly.com
1. Medicare now covers Cyberknife radiosurgery treatment for prostate cancer in most parts of the United States.2. The Cyberknife has specific advantages over conventional surgery and conventional radiotherapy/IMRT for prostate cancer.3. Early clinical results on the use of Cyberknife radiosurgeryfor...
Death due to HPV vaccine....NOT
October 2, 2009
GSK recalls Cervarix batch after reports of death due to cervical cancer vaccination in UK | www.pharmabiz.com
Today's news was that patient who reportedly died 2 hours after an HPV vaccine had a tumor in her chest and died of that cause. The vaccine was circumstantial.
Researchers herald 'breakthrough' skin cancer therapy
September 27, 2009
Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com
Plexxikon's early stage experimental melanoma drug PLX4032 looks like a "major breakthrough," says one leading researcher after reviewing new data from a small trial.
Mobile Advertising Set To Soar ? Yes, But What Is The Engine For Growth
November 17, 2009
Roche Receives H1N1 FDA Emergency Use Authorization
November 16, 2009
From a physician point of view
November 16, 2009
Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?
November 15, 2009
November 15, 2009
www.medscape.com
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today
www.medicalnewstoday.com
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology
www.pipelinereview.com
www.nytimes.com
www.docguide.com
FDA: Ongoing Omalizumab Study Shows Increased Number of Cardiovascular Events